Patients With a Recurrence Score of 11 to 25 May Not Benefit from Chemo
Patients with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer who have a recurrence score of 11 to 25 may not benefit from chemotherapy.
Patients with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer who have a recurrence score of 11 to 25 may not benefit from chemotherapy.
Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.
Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.
Researchers observed a significant disparity in colon cancer mortality related to origin location, independent of confounding variables.
The United States has remained near the bottom of the Bloomberg Health-Care Efficiency Index since its creation in 2012.
The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.
Insurance status influences overall patient survival for some cancer types, but its impact on glioblastoma multiforme (GBM) survival is well documented. This research study explored the possible impact of insurance on GBM survival.
A recent study examined the possible correlation between Medicaid coverage status and overall survival for patients with head and neck cancer.
A post-hoc analysis of the Phase 3 ASPIRE study indicates that treatment combining carfilzomib with lenalidomide and dexamethasone extended survival time for patients with multiple myeloma.
Greatest survival benefit observed for those taking the drug before their cancer diagnosis.